Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P34059
UPID:
GALNS_HUMAN
Alternative names:
Chondroitinsulfatase; Galactose-6-sulfate sulfatase; N-acetylgalactosamine-6-sulfate sulfatase
Alternative UPACC:
P34059; Q86VK3
Background:
N-acetylgalactosamine-6-sulfatase, known by alternative names such as Chondroitinsulfatase and Galactose-6-sulfate sulfatase, plays a crucial role in the lysosomal degradation of keratan sulfate and chondroitin-6-sulfate. This enzyme's activity is essential for the normal turnover of these glycosaminoglycans in the body.
Therapeutic significance:
The enzyme's deficiency is directly linked to Mucopolysaccharidosis 4A, a severe lysosomal storage disorder characterized by skeletal dysplasia, corneal clouding, and short stature, without affecting intelligence. Understanding the enzyme's function could lead to targeted therapies for this debilitating condition, potentially improving patient outcomes and quality of life.